Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) Insider Sells 94,124 Shares of Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) insider Johannes Jacob Piete Kastelein sold 94,124 shares of the company’s stock in a transaction on Friday, March 6th. The stock was sold at an average price of $30.32, for a total value of $2,853,839.68. Following the completion of the sale, the insider owned 69,302 shares of the company’s stock, valued at $2,101,236.64. This trade represents a 57.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Johannes Jacob Piete Kastelein also recently made the following trade(s):

• On Monday, March 9th, Johannes Jacob Piete Kastelein sold 101,409 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $30.29, for a total value of $3,071,678.61.
• On Thursday, March 5th, Johannes Jacob Piete Kastelein sold 104,467 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $30.30, for a total value of $3,165,350.10.
• On Friday, February 20th, Johannes Jacob Piete Kastelein sold 45,481 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $35.31, for a total value of $1,605,934.11.
• On Monday, January 5th, Johannes Jacob Piete Kastelein sold 6,000 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $33.25, for a total value of $199,500.00.

NewAmsterdam Pharma Price Performance

Shares of NASDAQ:NAMS traded up $0.91 during trading on Monday, hitting $30.77. 761,265 shares of the company’s stock were exchanged, compared to its average volume of 827,191. NewAmsterdam Pharma Company N.V. has a 52-week low of $14.06 and a 52-week high of $42.00. The business’s 50-day simple moving average is $33.48 and its 200 day simple moving average is $33.32. The company has a market cap of $3.54 billion, a price-to-earnings ratio of -17.79 and a beta of 0.04.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings results on Wednesday, February 18th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.23). NewAmsterdam Pharma had a negative return on equity of 26.67% and a negative net margin of 906.22%.The business had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.92 million. On average, sell-side analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Wall Street Zen cut shares of NewAmsterdam Pharma from a “hold” rating to a “sell” rating in a research note on Saturday, February 21st. Leerink Partners reiterated an “outperform” rating and issued a $55.00 price target on shares of NewAmsterdam Pharma in a research note on Tuesday, January 6th. The Goldman Sachs Group increased their price objective on shares of NewAmsterdam Pharma from $30.00 to $37.00 and gave the company a “neutral” rating in a report on Tuesday, December 2nd. Cantor Fitzgerald restated an “overweight” rating on shares of NewAmsterdam Pharma in a research report on Thursday, February 19th. Finally, Royal Bank Of Canada lifted their target price on NewAmsterdam Pharma from $44.00 to $47.00 and gave the stock an “outperform” rating in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $47.10.

Institutional Investors Weigh In On NewAmsterdam Pharma

Several large investors have recently bought and sold shares of NAMS. Jennison Associates LLC raised its stake in NewAmsterdam Pharma by 42.5% during the third quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock valued at $119,407,000 after purchasing an additional 1,252,451 shares in the last quarter. Atle Fund Management AB grew its stake in shares of NewAmsterdam Pharma by 23.2% in the 3rd quarter. Atle Fund Management AB now owns 193,625 shares of the company’s stock worth $5,507,000 after buying an additional 36,402 shares in the last quarter. Keybank National Association OH purchased a new position in shares of NewAmsterdam Pharma in the 3rd quarter worth $455,000. Franklin Resources Inc. increased its holdings in shares of NewAmsterdam Pharma by 30.6% in the 2nd quarter. Franklin Resources Inc. now owns 334,212 shares of the company’s stock worth $6,053,000 after buying an additional 78,300 shares during the last quarter. Finally, Handelsbanken Fonder AB raised its position in shares of NewAmsterdam Pharma by 18.8% during the 3rd quarter. Handelsbanken Fonder AB now owns 405,800 shares of the company’s stock valued at $11,541,000 after buying an additional 64,200 shares in the last quarter. Institutional investors own 89.89% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.